(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People's Republic of China...
Stats | |
---|---|
आज की मात्रा | 10.09M |
औसत मात्रा | 17.65M |
बाजार मूल्य | 14.58B |
EPS | HKD0 ( 2024-03-20 ) |
अगली कमाई की तारीख | ( HKD0 ) 2024-06-19 |
Last Dividend | HKD0.100 ( 2023-06-27 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 9.07 |
ATR14 | HKD0.0120 (0.20%) |
मात्रा सहसंबंध
3SBio Inc सहसंबंध
10 सबसे अधिक सकारात्मक सहसंबंध |
---|
10 सबसे अधिक नकारात्मक सहसंबंध |
---|
क्या आप जानते हैं?
कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।
कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।
3SBio Inc सहसंबंध - मुद्रा/वस्त्र
3SBio Inc वित्तीय
Annual | 2023 |
राजस्व: | HKD7.82B |
सकल लाभ: | HKD6.64B (84.98 %) |
EPS: | HKD0.620 |
FY | 2023 |
राजस्व: | HKD7.82B |
सकल लाभ: | HKD6.64B (84.98 %) |
EPS: | HKD0.620 |
FY | 2022 |
राजस्व: | HKD6.86B |
सकल लाभ: | HKD5.67B (82.69 %) |
EPS: | HKD0.780 |
FY | 2021 |
राजस्व: | HKD6.38B |
सकल लाभ: | HKD5.28B (82.67 %) |
EPS: | HKD0.650 |
Financial Reports:
No articles found.
3SBio Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.100 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.0685 | 2018-06-29 |
Last Dividend | HKD0.100 | 2023-06-27 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 3 | -- |
Total Paid Out | HKD0.369 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.64 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 5.29 | |
Div. Directional Score | 8.05 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
2270.HK | Ex Dividend Junior | 2023-06-26 | Insufficient data to determine frequency | 0 | 0.00% | |
1263.HK | Ex Dividend Junior | 2023-09-14 | Annually | 0 | 0.00% | |
0321.HK | Ex Dividend Knight | 2023-08-31 | Semi-Annually | 0 | 0.00% | |
6033.HK | Ex Dividend Knight | 2023-09-19 | Semi-Annually | 0 | 0.00% | |
1818.HK | Ex Dividend Junior | 2023-06-07 | Annually | 0 | 0.00% | |
0848.HK | Ex Dividend Junior | 2023-05-24 | Annually | 0 | 0.00% | |
0006.HK | Ex Dividend Knight | 2023-08-30 | Semi-Annually | 0 | 0.00% | |
2588.HK | Ex Dividend Knight | 2023-09-25 | Semi-Annually | 0 | 0.00% | |
1382.HK | Ex Dividend Knight | 2023-08-15 | Semi-Annually | 0 | 0.00% | |
0455.HK | Ex Dividend Junior | 2023-06-29 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.198 | 1.500 | 6.04 | 9.05 | [0 - 0.5] |
returnOnAssetsTTM | 0.0656 | 1.200 | 7.81 | 9.38 | [0 - 0.3] |
returnOnEquityTTM | 0.112 | 1.500 | 9.86 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 2.47 | 0.800 | 2.67 | 2.14 | [1 - 3] |
quickRatioTTM | 1.901 | 0.800 | 3.52 | 2.82 | [0.8 - 2.5] |
cashRatioTTM | 0.722 | 1.500 | 7.10 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.204 | -1.500 | 6.59 | -9.89 | [0 - 0.6] |
interestCoverageTTM | 23.36 | 1.000 | 2.46 | 2.46 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.485 | 2.00 | 9.84 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.353 | 2.00 | 9.82 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.344 | -1.500 | 8.62 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.850 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.300 | 1.000 | 5.99 | 5.99 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.245 | 1.000 | 9.75 | 9.75 | [0.2 - 2] |
assetTurnoverTTM | 0.331 | 0.800 | -1.128 | -0.902 | [0.5 - 2] |
Total Score | 10.81 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 8.87 | 1.000 | 9.21 | 0 | [1 - 100] |
returnOnEquityTTM | 0.112 | 2.50 | 9.91 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.353 | 2.00 | 9.88 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.778 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.485 | 2.00 | 9.84 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.152 | 1.000 | 8.71 | 0 | [0.1 - 0.5] |
Total Score | 5.29 |
3SBio Inc
3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People's Republic of China. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; EPIAO and SEPO recombinant human erythropoietins to treat anemia; and Cipterbin for HER2-positive metastatic breast cancer in combination with chemotherapy. It also offers Mandi to treat male alopecia and alopecia areata; Xenopax for preventing acute rejection after renal transplant; Byetta for the glycemic control in patients with type 2 diabetes; Qiming Keli to treat retinopathy caused by type 2 diabetic; Aiyishu for iron-deficiency anemia; and SPARIN, an injectable low-molecular-weight heparin calcium for the treatment of prophylaxis and deep vein thrombosis, as well as for the prevention of clotting during hemodialysis. In addition, it offers Intefen, a recombinant human interferon to treat lymphatic or hematopoietic malignancies and viral infections; and Inleusin, a human interleukin2 for the treatment of renal cell carcinoma, melanoma, and thoracic fluid build-up. Further, the company provides trading, project management and consultation, technology, and agricultural services. It has collaboration agreements with companies, such as AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and DanaFarber Cancer Institute. The company was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.
के बारे में लाइव सिग्नल्स
इस पृष्ठ पर प्रस्तुत लाइव सिग्नल्स NA को कब खरीदना या बेचना है, इसका निर्धारण करने में मदद करते हैं। सिग्नल्स में 1-मिनट की देरी हो सकती है; सभी बाजार सिग्नल्स की तरह, त्रुटि या गलतियों की संभावना होती है।
लाइव ट्रेडिंग सिग्नल्स स्थायी नहीं हैं, और getagraph.com इन सिग्नल्स पर किए गए किसी भी कार्रवाई के लिए जिम्मेदारी नहीं रखते हैं, जैसा कि उपयोग की शर्तें में वर्णित है। सिग्नल्स एक व्यापक श्रृंखला के तकनीकी विश्लेषण संकेतकों पर आधारित हैं